CFTR and cystic fibrosis: In summary, these two large, international phase 3 trials show that vanzacaftor–tezacaftor–deutivacaftor, a novel, once-daily, triple combination CFTR modulator therapy, was non-inferior in terms of change from baseline in lung function and superior in improvements in sweat chloride concentrations compared with the current standard of care, elexacaftor–tezacaftor–ivacaftor, in eligible people with cystic fibrosis.